Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis
NCT ID: NCT01986920
Last Updated: 2018-12-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
35 participants
INTERVENTIONAL
2013-10-22
2014-02-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A-101 25%
Low dose group
A-101 25%
Low Dose Concentration of A-101 applied to one of 4 Target Lesions
A-101 32.5%
Mid Dose Group
A-101 32.5%
Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
A-101 40%
High Dose Group
A-101 40%
High Dose Concentration A-101 applied to one of 4 Target Lesions
A-101 Vehicle
Placebo group
A-101 Vehicle
Placebo applied to one of 4 Target Lesions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
A-101 25%
Low Dose Concentration of A-101 applied to one of 4 Target Lesions
A-101 32.5%
Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
A-101 40%
High Dose Concentration A-101 applied to one of 4 Target Lesions
A-101 Vehicle
Placebo applied to one of 4 Target Lesions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Has a clinical diagnosis of stable clinically typical seborrheic keratosis
3. Has at least 4 appropriate seborrheic keratosis target lesions on the back
4. If subject is a women of childbearing potential, she must have a negative urine pregnancy test and must agree to use an active form of birth control for the duration of the study
5. Is non-pregnant and non-lactating
6. Is in good general health and free of any disease state or physical condition which, in the investigator's opinion, might impair evaluation of any target lesion or which exposes the subject to an unacceptable risk by study participation
7. Is willing and able to follow all study instructions and to attend all study visits
8. Is able to comprehend and willing to sign an Informed Consent Form (ICF).
Exclusion Criteria
2. Has presence of multiple eruptive seborrheic keratosis lesions (Sign of Leser-Trelat)
3. Has used any of the following systemic therapies within the specified period prior to Visit 1:
* Retinoids; 180 days
* Glucocorticosteroids; 28 days
* Anti-metabolites (e.g., methotrexate); 28 days
4. Has used any of the following topical therapies on the treatment area within the specified period prior to Visit 1:
* Retinoids; 90 days
* Liquid nitrogen, electrodesiccation, curettage, imiquimod, 5-fluorouracil, or ingenol mebutate; 60 days
* Glucocorticosteroids or antibiotics; 14 days
* Moisturizers/emollients, sunscreens; 12 hours
5. Has had any LASER, light (e.g., intense pulsed light (IPL), photo-dynamic therapy (PDT)) or other energy based therapy on the treatment area within 180 days prior to Visit 1
6. Has a history of keloid formation or hypertrophic scarring
7. Has a current systemic malignancy
8. Has a history of, within the 180 days prior to Visit 1, or has a current cutaneous malignancy on the treatment area
9. Has a current pre-malignancy (e.g., actinic keratosis) on the treatment area
10. Has had body art (e.g., tattoos, piercing, sculpting, etc.) or any other invasive, non-therapeutic procedure performed on the treatment area that, in the opinion of the investigator, might put the subject at undue risk or interfere with the study conduct or evaluations
11. Has excessive tan on the treatment area that, in the opinion of the investigator, might put the subject at undue risk or interfere with the study conduct or evaluations
12. Has experienced a sunburn on the treatment area within the previous 4 weeks
13. Has a history of sensitivity to any of the ingredients in the study medications
14. Has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.), or condition (e.g., sunburn, tattoos, excessive hair, open wounds on the back) that, in the opinion of the investigator, might put the subject at undue risk or interfere with the study conduct or evaluations
15. Has participated in an investigational drug trial in which administration of an investigational study medication occurred within 30 days prior to Visit 1.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aclaris Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janet Dubois, MD
Role: PRINCIPAL_INVESTIGATOR
Derm Research, PLLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
DermResearch, Inc.
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Study Sponsor Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A-101-SEBK-201
Identifier Type: -
Identifier Source: org_study_id